Yuhan Corporation

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 2025-06-16			5-day change	1st Jan Change
106,300.00 ^KRW	-0.19%		+2.41%	-11.05%

06-10	Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. for KRW 14.2 billion.	CI
06-09	Yuhan to Receive KRW20.7 Billion Milestone from Janssen for Japan Launch of Lung Cancer Drug Combo	MT

Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024.

Published on 2023-07-27 at 18:00

On July 28, 2023, the company announced that it has extended its plan duration till July 31, 2024.

Latest news about Yuhan Corporation

Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. for KRW 14.2 billion.	06-10	CI
Yuhan to Receive KRW20.7 Billion Milestone from Janssen for Japan Launch of Lung Cancer Drug Combo	06-09	MT
South Korean Shares Decline on US Debt Concerns	05-22	MT
Yuhan Secures HIV API Supply Contract with Gilead Sciences	05-21	MT
Yuhan Corp Wins 89 Billion Won Order	05-21	RE
Yuhan to Retire KRW25.3 Billion Worth of Treasury Stocks to Raise Shareholder Value	05-13	MT
Yuhan Corp To Cancel 25.3 Billion Won Worth Of Own Shares	05-12	RE
Yuhan Corp Q1 Operating Profit 8.6 Billion Won, Up 40.8% From Year Earlier	05-08	RE
Progen Co., Ltd. announced that it has received KRW 22.0999869 billion in funding from Yuhan Corporation, SL Bigen Co., Ltd., JW Pharmaceutical Corporation	04-24	CI
Progen Co., Ltd. announced that it expects to receive KRW 22.0999869 billion in funding from Yuhan Corporation, SL Bigen Co., Ltd., JW Pharmaceutical Corporation	04-16	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 2022.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 2022.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 2022.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on February 16, 2022.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on July 29, 2021.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on May 30, 2012.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on October 26, 2011.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on August 9, 2011.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on March 12, 2010.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on October 29, 2009.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on November 27, 2003.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on December 13, 2002.	04-03	CI
Tranche Update on Yuhan Corporation's Equity Buyback Plan announced on January 11, 2000.	04-03	CI
Yuhan Corporation 's Equity Buyback announced on August 9, 2011 has closed with 887,700 shares, representing 1.13% for KRW 22,562.81 million.	03-30	CI
Yuhan Corporation's Equity Buyback announced on February 16, 2022, has closed with 355,967 shares, representing 0.47% for KRW 20,012 million.	03-30	CI

Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Employees

2,038

Sector

Pharmaceuticals

Calendar

09:00pm - Non Deal Roadshow

More about the company